Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ImmunoMet

ImmunoMet
2015 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$5M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of novel anti-tumor and immuno-oncology therapies created to treat cancer patients. The company's novel anti-tumor and immuno-oncology therapies includes oncology drugs and metabolic regulators to increase patient survival by disrupting cancer metabolism and enhancing anti-cancer immunity targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • JLABS at Texas Medical Center
  • 2450 Holcombe Boulevard
  • Houston, TX 77021
  • United States

+1 (346) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ImmunoMet’s full profile, request a free trial.

ImmunoMet Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 07-Mar-2017 $5M 000.00 0000 Completed Clinical Trials - General
3. Accelerator/Incubator 02-Mar-2016 00.00 Completed Startup
2. Early Stage VC (Series A) 05-Feb-2016 $5.2M $6.2M 000.00 Completed Startup
1. Seed Round 01-Aug-2015 $1M $1M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

ImmunoMet Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00 00 00 00.000
Seed 800,000 $0.001000 $1.25 $1.25 1x $1.25 21.92%
To view this company’s complete Cap Table, request access »

ImmunoMet Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
InterVest Venture Capital Minority 000 0000 000000 0
NHN Capital Venture Capital Minority 000 0000 000000 0
SL Investment Venture Capital Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
Aju Tech Other Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

ImmunoMet Executive Team (14)

Name Title Board
Seat
Contact
Info
Sung-wuk Kim Board Member, Chairman & Chief Executive Officer
Benjamin Cowen Ph.D Chief Operating Officer
Sanghee Yoo Ph.D Vice President Head of Biology
Anthony Horning Head of Business Development, Licensing & Business Advisor
Jae-Ho Cheong MD Advisor

3 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

ImmunoMet Board Members (5)

Name Representing Role Since Contact
Info
Bongyong Lee Ph.D Self Board Member 000 0000
Jae-Joon Kim Mirae Asset Venture Investment Board Member 000 0000
Sung-wuk Kim ImmunoMet Board Member, Chairman & Chief Executive Officer 000 0000
Tae Lee InterVest Board Member 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »